Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MK-0822 in Women with Breast Cancer and Bone Metastases
2006-002669-38Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of odanacatib in breast cancer and bone metastases, sponsored by Merck & Co. Primary endpoints: Urinary NTx and Safety and tolerability. Started Sep 2006; status: completed.
02
Drugs
odanacatib
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2006-002669-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002669-38.